Elevated Opioid Use During Pregnancy in New Zealand: A Growing Concern
New Zealand ranks third among high-income countries for prescribed opioid use during pregnancy, with nearly 8% of pregnancies affected, raising concerns about potential fetal risks and the need for updated guidelines.
Recent research highlights that New Zealand ranks third among high-income countries for prescribed opioid use during pregnancy, with almost 8% of pregnancies exposed to opioids. This rate is notably higher than in several other nations, such as Canada and the UK. The study, led by the University of New South Wales and published in the journal Anesthesiology, analyzed prescription data from over 20 million pregnancies worldwide, spanning from 2000 to 2020.
The investigation utilized anonymized prescription records from countries including Australia, New Zealand, Canada, the US, and European nations, revealing that opioid use remained stable or declined slightly in most countries over the two decades. The highest consumption was observed in the United States, while the United Kingdom had the lowest rates. Among the opioids most commonly used were codeine and tramadol.
Interestingly, opioid use was more prevalent during late pregnancy and among women with lower income levels and higher body mass index. Furthermore, the study noted an overall increase in prescription medication use during pregnancy over the 20-year period, possibly linked to an aging pregnant population with more medical conditions requiring treatment.
Dr. Sarah Donald from the University of Otago emphasized that these findings raise important questions about current guidelines and practices surrounding opioid prescription during pregnancy. She and her colleagues highlighted that, although 80% of pregnant women using opioids received only a single prescription, potential risks remain significant.
Professor Lianne Parkin added that opioids can cross the placenta, exposing the fetus to risks associated with early exposure, such as congenital malformations, preterm birth, low birth weight, neonatal breathing difficulties, withdrawal symptoms, and longer-term neurodevelopmental issues. These findings underscore the importance of carefully evaluating the necessity of opioid use during pregnancy and exploring safer pain management alternatives.
This comprehensive study underscores the need for ongoing review of prescribing practices and underscores the importance of balancing effective pain relief with potential risks to both mother and child.
Source: https://medicalxpress.com/news/2025-05-high-opioid-nz-pregnancies.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
FDA Approves Effective Topical Foam for Treating Scalp and Body Plaque Psoriasis
The FDA has approved Zoryve foam, a steroid-free topical treatment for scalp and body plaque psoriasis in adolescents and adults, backed by clinical trial success in clearing psoriasis and relieving itching.
New Study Connects Pesticide Exposure to Increased Mortality in Children
A groundbreaking study links prenatal pesticide exposure to higher mortality risk in children with leukemia, highlighting the urgent need to reduce environmental toxicants affecting children's health.
Revolutionizing Transplant Diagnostics with AI-Driven Virtual Tissue Staining
A novel AI-based virtual staining technique enhances transplant biopsy analysis by providing rapid, cost-effective, and reliable tissue diagnostics, improving outcomes for transplant patients.
New Insights into Childhood Kidney Cancer Reveal Extensive Genetic Alterations
New genomic research uncovers millions of genetic mutations in childhood kidney tumors, paving the way for personalized treatments and improved outcomes.